Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

Amplia has announced that a fifth patient enrolled in the Company’s ACCENT clinical trial in pancreatic cancer has recorded a confirmed partial response, meaning a 30% or greater decrease in the overall size of tumour lesions maintained over a two-month period, and with no new tumour lesions.

A total of 50 patients are planned for the Phase 2a ACCENT trial. A minimum of six patients who record a confirmed partial or complete response are required before recruitment of the second cohort of 24 patients can begin. Only one additional confirmed response is now required to trigger the interim analysis for the first cohort in the trial.

Amplia CEO and MD Dr Chris Burns commented:

“The continued positive data from the trial is extremely gratifying and at this rate we remain confident we will reopen recruitment in early October.”

Click link below to read the full ASX Release.

Fifth partial response confirmed in ACCENT trial